Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma: a Multicenter, Prospective, Randomized Controlled Trial
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Temozolomide (Primary)
- Indications Acral lentiginous melanoma
- Focus Therapeutic Use
- 04 Sep 2023 Status changed from not yet recruiting to recruiting.
- 31 Mar 2023 New trial record